Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{189875,
        author = {Yogesh Kailas Palhal and Amanpreet Kaur Dumda Palaya},
        title = {A comprehensive review on acyclovir self-emulsifying buccal nano-film (SEBNF): a novel hybrid drug delivery approach for enhancing bioavailability of BCS class IV drugs},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {2664-2668},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=189875},
        abstract = {Acyclovir is a widely prescribed antiviral drug used in the treatment of infections caused by herpes simplex virus and varicella-zoster virus. Although acyclovir exhibits strong antiviral activity and a well-established safety profile, its clinical performance is significantly compromised by poor aqueous solubility, low epithelial permeability, and variable gastrointestinal absorption. These limitations categorize acyclovir as a Biopharmaceutics Classification System (BCS) Class IV drug. Conventional oral dosage forms often result in low and inconsistent bioavailability, requiring frequent administration and leading to reduced patient compliance. Over the past few decades, numerous formulation strategies have been explored to overcome these drawbacks; however, most approaches focus on either solubility enhancement or permeability improvement alone. Self-emulsifying buccal nano-film (SEBNF) systems represent a novel hybrid drug delivery strategy that integrates the solubilization advantages of self-emulsifying drug delivery systems with the benefits of buccal transmucosal delivery, including avoidance of first-pass metabolism and rapid systemic absorption. This review provides a comprehensive and critical evaluation of the biopharmaceutical challenges associated with acyclovir, summarizes relevant literature on buccal and self- emulsifying delivery systems, and highlights the scientific rationale for SEBNF as a promising platform for improving the bioavailability of BCS Class IV drugs.},
        keywords = {Acyclovir, Self-emulsifying drug delivery system, Buccal nano-film, BCS Class IV drugs, Bioavailability enhancement.},
        month = {January},
        }